# Barinthus Biotherapeutics plc.

Barinthus Biotherapeutics plc. is a company headquartered in Germantown, MD, United States.

## Company overview

- **Legal name:** Barinthus Biotherapeutics plc.
- **Former names in filing history:** Vaccitech plc (2021-01-19 to 2023-10-05); Vaccitech Ltd (2020-12-23 to 2021-03-23)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Germantown, MD, United States
- **Incorporated in:** X0
- **Fiscal year end:** December 31
- **SEC CIK:** 0001828185

## About

Barinthus Biotherapeutics plc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001828185, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-03-13, it reported annual revenue of USD 0; net income of USD -66,428,000; total assets of USD 98,169,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$66.4M (USD -66,428,000)
- **Total assets:** $98.2M (USD 98,169,000)
- **Cash and equivalents:** $70.5M (USD 70,456,000)
- **Operating cash flow:** -$48.0M (USD -47,979,000)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $15.0M (USD 14,969,000)
- **Net income:** -$61.1M (USD -61,074,000)
- **Total assets:** $160.3M (USD 160,327,000)
- **Cash and equivalents:** $110.7M (USD 110,662,000)
- **Operating cash flow:** -$28.9M (USD -28,940,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $802,000 (USD 802,000)
- **Net income:** -$73.3M (USD -73,347,000)
- **Total assets:** $214.5M (USD 214,506,000)
- **Cash and equivalents:** $142.1M (USD 142,090,000)
- **Operating cash flow:** -$50.9M (USD -50,925,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $44.7M (USD 44,703,000)
- **Net income:** $5.3M (USD 5,342,000)
- **Total assets:** $270.2M (USD 270,205,000)
- **Cash and equivalents:** $194.4M (USD 194,385,000)
- **Operating cash flow:** -$14.4M (USD -14,431,000)

## Recent SEC filings

- Form 8-K — filed 2026-09-09 — period 2026-09-09 — FORM 8-K
- Form 8-K — filed 2026-09-01 — period 2026-09-01 — FORM 8-K
- Form 8-K — filed 2026-08-25 — period 2026-08-24 — FORM 8-K
- Form 8-K — filed 2026-08-06 — period 2026-08-06 — 8-K
- Form 10-Q — filed 2026-08-06 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-07-02 — period 2026-06-30 — FORM 8-K
- Form DEF 14A — filed 2026-06-10 — period 2026-07-02 — DEF 14A
- Form 8-K — filed 2026-05-21 — period 2026-05-20 — FORM 8-K
- Form 10-Q — filed 2026-04-30 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-04-30 — period 2026-04-30 — 8-K
- Form 8-K — filed 2026-04-22 — period 2026-04-22 — FORM 8-K
- Form 8-K — filed 2026-03-31 — period 2026-03-27 — FORM 8-K

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/barinthus-biotherapeutics-plc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology